- Home
- ABEO vs CLLS Comparison
ABEO vs CLLS Comparison
Compare ABEO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | CLLS |
|---|---|---|
| Founded | 1974 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 485.6M |
| IPO Year | 1980 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ABEO | CLLS |
|---|---|---|
| Price | $5.45 | $4.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $18.20 | $8.50 |
| AVG Volume (30 Days) | ★ 1.2M | 112.6K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | $400,000.00 | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $1,589.77 | $20.68 |
| P/E Ratio | $4.24 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $3.93 | $1.10 |
| 52 Week High | $7.54 | $5.48 |
Technical Indicators
Market Signals| Indicator | ABEO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 54.48 |
| Support Level | $4.80 | $4.47 |
| Resistance Level | $5.55 | $5.03 |
| Average True Range (ATR) | 0.26 | 0.28 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 80.75 | 54.55 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.